A Novel Bispecific T Cell Engager (UMG2BTCE) Targeting CD1a-CD3e Is Effective Against Cortical-Derived Acute Lymphoblastic Leukemia

被引：0
|
作者：
Riillo, Caterina [1 ]
Caracciolo, Daniele [1 ]
Grillone, Katia [1 ]
Polera, Nicoletta [1 ]
Juli, Giada [1 ]
Scionti, Francesca [2 ]
Ascrizzi, Serena [1 ]
Tuccillo, Franca Maria [3 ]
Bonelli, Patrizia [3 ]
Arbitrio, Mariamena [4 ]
Di Martino, Maria Teresa [1 ]
Tagliaferri, Pierosandro [1 ]
Tassone, Pierfrancesco [1 ,5 ]
机构：
[1] Magna Graecia Univ Catanzaro, Catanzaro, Italy
[2] Italian Natl Council CNR, IRIB, Messina, Italy
[3] Ist Nazl Tumori Fdn G Pascale, Naples, Italy
[4] IRIB CNR, Catanzaro, Italy
[5] Sbarro Inst Canc Res & Mol Med, Ctr Biotechnol, Philadelphia, PA USA
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-153043
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2259
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Induction of NK and T cell immune responses against acute myeloid leukemia (AML) by bispecific NKG2D-CD16 and NKG2D-CD3 fusion proteins
    Maurer, S.
    Koerner, S.
    Kanz, L.
    Grosse-Hovest, L.
    Jung, G.
    Salih, H. R.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 315 - 315
  • [42] A Phase 1 Study of CD38-Bispecific Antibody (XmAb18968) for Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia
    Murthy, Guru Subramanian Guru
    Shah, Bijal D.
    Duvall, Adam S.
    Leonard, Jessica T.
    Badar, Talha
    Yi, Cecilia Y. Arana
    Kearl, Tyce
    Baim, Arielle
    Harrington, Alexandra M.
    Szabo, Aniko
    Atallah, Ehab L.
    BLOOD, 2023, 142
  • [43] A Novel Fc-Optimized Antibody Drug Conjugate Targeting CD7 As a Therapeutic Strategy in T-Cell Acute Lymphoblastic Leukemia
    Gehlert, Carina Lynn
    Schewe, Denis Martin
    Klausz, Katja
    Krohn, Steffen
    Winterberg, Dorothee
    Vogiatzi, Fotini
    Boje, Ammelie Svea
    Lux, Anja
    Nimmerjahn, Falk
    Scherliess, Regina
    Humpe, Andreas
    Schrappe, Martin
    Cario, Gunnar
    Valerius, Thomas
    Fransecky, Lars
    Brueggemann, Monika
    Baldus, Claudia D.
    Gramatzki, Martin
    Lenk, Lennart
    Kellner, Christian
    Peipp, Matthias
    BLOOD, 2023, 142
  • [44] Phase II Trial of the Anti-CD19 Bispecific T Cell-Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia
    Topp, Max S.
    Gokbuget, Nicola
    Zugmaier, Gerhard
    Klappers, Petra
    Stelljes, Matthias
    Neumann, Svenja
    Viardot, Andreas
    Marks, Reinhard
    Diedrich, Helmut
    Faul, Christoph
    Reichle, Albrecht
    Horst, Heinz-August
    Brueggemann, Monika
    Wessiepe, Dorothea
    Holland, Chris
    Alekar, Shilpa
    Mergen, Noemi
    Einsele, Hermann
    Hoelzer, Dieter
    Bargou, Ralf C.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (36) : 4134 - U363
  • [45] Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab
    Klinger, Matthias
    Brandl, Christian
    Zugmaier, Gerhard
    Hijazi, Youssef
    Bargou, Ralf C.
    Topp, Max S.
    Goekbuget, Nicola
    Neumann, Svenja
    Goebeler, Mariele
    Viardot, Andreas
    Stelljes, Matthias
    Brueggemann, Monika
    Hoelzer, Dieter
    Degenhard, Evelyn
    Nagorsen, Dirk
    Baeuerle, Patrick A.
    Wolf, Andreas
    Kufer, Peter
    BLOOD, 2012, 119 (26) : 6226 - 6233
  • [46] Anti-IL1RAP/CD3 Bispecific Antibody (BsAb) Is a Promising Novel and Effective Therapy for Acute Myeloid Leukemia (AML)
    Meng, Weixu
    Del Real, Marissa
    Wei, Guowei
    Hernandez, Rochelle
    Marcucci, Emanuela
    Lin, Allen
    Mcdonald, Tinisha
    Zhao, Dandan
    Wu, Herman
    Carlesso, Nadia
    Kwak, Larry W.
    Li, Ling
    Kuo, Ya-Huei
    Stein, Anthony S.
    Pullarkat, Vinod
    Nakamura, Ryotaro
    Rosen, Steven T.
    Forman, Stephen J.
    Zhang, Bin
    Budde, Lihua
    Marcucci, Guido
    BLOOD, 2017, 130
  • [47] A CH2CH3 hinge region enhances the cytotoxicity of anti-CD5 CAR-T cells targeting T cell acute lymphoblastic leukemia
    Wu, Huantong
    Yu, Yajie
    Zhao, Yu
    Liu, Weihua
    Liu, Zhongfeng
    Zhang, Guangji
    Chen, Zhiguo
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 124
  • [48] ABBV-184: A Novel Survivin-specific TCR/CD3 Bispecific T-cell Engager is Active against Both Solid Tumor and Hematologic Malignancies
    Chervin, Adam S.
    Stone, Jennifer D.
    Konieczna, Iwona
    Calabrese, Kelly M.
    Wang, Ningyan
    Haribhai, Dipica
    Dong, Feng
    White, Michael K.
    Rodriguez, Luis E.
    Bukofzer, Gail T.
    Ellis, Paul A.
    Cosgrove, Cormac
    Hecquet, Claudie
    Clarin, Jerry D.
    Palma, Joann P.
    Reilly, Edward B.
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (08) : 903 - 912
  • [49] Pretreatment blast-to-lymphocyte ratio as a prognostic marker for CD19/CD3-bispecific T cell-engaging antibodies (blinatumomab) treatment against relapsed or refractory B-precursor acute lymphoblastic leukemia
    Shimazu, Yutaka
    Kitawaki, Toshio
    Kondo, Tadakazu
    Takaori-Kondo, Akifumi
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (11) : 3861 - 3865
  • [50] Pretreatment blast-to-lymphocyte ratio as a prognostic marker for CD19/CD3-bispecific T cell-engaging antibodies (blinatumomab) treatment against relapsed or refractory B-precursor acute lymphoblastic leukemia
    Yutaka Shimazu
    Toshio Kitawaki
    Tadakazu Kondo
    Akifumi Takaori-Kondo
    Cancer Immunology, Immunotherapy, 2023, 72 : 3861 - 3865
12345